Literature DB >> 30366930

IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.

Giulia Biffi1,2, Tobiloba E Oni1,2, Benjamin Spielman1,2, Yuan Hao1, Ela Elyada1,2, Youngkyu Park1,2, Jonathan Preall1, David A Tuveson3,2.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is poorly responsive to therapies and histologically contains a paucity of neoplastic cells embedded within a dense desmoplastic stroma. Within the stroma, cancer-associated fibroblasts (CAF) secrete tropic factors and extracellular matrix components, and have been implicated in PDAC progression and chemotherapy resistance. We recently identified two distinct CAF subtypes characterized by either myofibroblastic or inflammatory phenotypes; however, the mechanisms underlying their diversity and their roles in PDAC remain unknown. Here, we use organoid and mouse models to identify TGFβ and IL1 as tumor-secreted ligands that promote CAF heterogeneity. We show that IL1 induces LIF expression and downstream JAK/STAT activation to generate inflammatory CAFs and demonstrate that TGFβ antagonizes this process by downregulating IL1R1 expression and promoting differentiation into myofibroblasts. Our results provide a mechanism through which distinct fibroblast niches are established in the PDAC microenvironment and illuminate strategies to selectively target CAFs that support tumor growth. SIGNIFICANCE: Understanding the mechanisms that determine CAF heterogeneity in PDAC is a prerequisite for the rational development of approaches that selectively target tumor-promoting CAFs. Here, we identify an IL1-induced signaling cascade that leads to JAK/STAT activation and promotes an inflammatory CAF state, suggesting multiple strategies to target these cells in vivo. See related commentary by Ling and Chiao, p. 173. This article is highlighted in the In This Issue feature, p. 151. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30366930      PMCID: PMC6368881          DOI: 10.1158/2159-8290.CD-18-0710

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  54 in total

1.  IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.

Authors:  Kristen B Long; Graham Tooker; Evan Tooker; Santiago Lombo Luque; Jae W Lee; Xiaoqing Pan; Gregory L Beatty
Journal:  Mol Cancer Ther       Date:  2017-06-13       Impact factor: 6.261

2.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

3.  Transforming growth factor-beta1 promotes the morphological and functional differentiation of the myofibroblast.

Authors:  M B Vaughan; E W Howard; J J Tomasek
Journal:  Exp Cell Res       Date:  2000-05-25       Impact factor: 3.905

4.  STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis.

Authors:  Ryan B Corcoran; Gianmarco Contino; Vikram Deshpande; Alexandros Tzatsos; Claudius Conrad; Cyril H Benes; David E Levy; Jeffrey Settleman; Jeffrey A Engelman; Nabeel Bardeesy
Journal:  Cancer Res       Date:  2011-05-17       Impact factor: 12.701

5.  CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.

Authors:  S Singh; S K Srivastava; A Bhardwaj; L B Owen; A P Singh
Journal:  Br J Cancer       Date:  2010-11-02       Impact factor: 7.640

6.  Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.

Authors:  Mara H Sherman; Ruth T Yu; Dannielle D Engle; Ning Ding; Annette R Atkins; Herve Tiriac; Eric A Collisson; Frances Connor; Terry Van Dyke; Serguei Kozlov; Philip Martin; Tiffany W Tseng; David W Dawson; Timothy R Donahue; Atsushi Masamune; Tooru Shimosegawa; Minoti V Apte; Jeremy S Wilson; Beverly Ng; Sue Lynn Lau; Jenny E Gunton; Geoffrey M Wahl; Tony Hunter; Jeffrey A Drebin; Peter J O'Dwyer; Christopher Liddle; David A Tuveson; Michael Downes; Ronald M Evans
Journal:  Cell       Date:  2014-09-25       Impact factor: 41.582

7.  STAT3 acts through pre-existing nucleosome-depleted regions bound by FOS during an epigenetic switch linking inflammation to cancer.

Authors:  Joseph D Fleming; Paul G Giresi; Marianne Lindahl-Allen; Elsa B Krall; Jason D Lieb; Kevin Struhl
Journal:  Epigenetics Chromatin       Date:  2015-02-14       Impact factor: 4.954

8.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Authors:  Ravid Straussman; Teppei Morikawa; Kevin Shee; Michal Barzily-Rokni; Zhi Rong Qian; Jinyan Du; Ashli Davis; Margaret M Mongare; Joshua Gould; Dennie T Frederick; Zachary A Cooper; Paul B Chapman; David B Solit; Antoni Ribas; Roger S Lo; Keith T Flaherty; Shuji Ogino; Jennifer A Wargo; Todd R Golub
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962

9.  Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity.

Authors:  Thomas R Flint; Tobias Janowitz; Claire M Connell; Edward W Roberts; Alice E Denton; Anthony P Coll; Duncan I Jodrell; Douglas T Fearon
Journal:  Cell Metab       Date:  2016-11-08       Impact factor: 27.287

10.  Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts.

Authors:  Jean Albrengues; Thomas Bertero; Eloise Grasset; Stephanie Bonan; Majdi Maiel; Isabelle Bourget; Claude Philippe; Cecilia Herraiz Serrano; Samia Benamar; Olivier Croce; Victoria Sanz-Moreno; Guerrino Meneguzzi; Chloe C Feral; Gael Cristofari; Cedric Gaggioli
Journal:  Nat Commun       Date:  2015-12-15       Impact factor: 14.919

View more
  292 in total

1.  Moderate alcohol intake promotes pancreatic ductal adenocarcinoma development in mice expressing oncogenic Kras.

Authors:  Kinji Asahina; Steven Balog; Edward Hwang; Eugene Moon; Emily Wan; Kaitlin Skrypek; Yibu Chen; Jay Fernandez; Janet Romo; Qihong Yang; Keane Lai; Samuel W French; Hidekazu Tsukamoto
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-11-25       Impact factor: 4.052

Review 2.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

3.  Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts.

Authors:  Mohan Bolisetty; Pasquale Laise; William F Flynn; Ela Elyada; Elise T Courtois; Richard A Burkhart; Jonathan A Teinor; Pascal Belleau; Giulia Biffi; Matthew S Lucito; Santhosh Sivajothi; Todd D Armstrong; Dannielle D Engle; Kenneth H Yu; Yuan Hao; Christopher L Wolfgang; Youngkyu Park; Jonathan Preall; Elizabeth M Jaffee; Andrea Califano; Paul Robson; David A Tuveson
Journal:  Cancer Discov       Date:  2019-06-13       Impact factor: 39.397

4.  Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells.

Authors:  Chenxi Tian; Karl R Clauser; Daniel Öhlund; Steffen Rickelt; Ying Huang; Mala Gupta; D R Mani; Steven A Carr; David A Tuveson; Richard O Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

Review 5.  Organoid models for translational pancreatic cancer research.

Authors:  Hervé Tiriac; Dennis Plenker; Lindsey A Baker; David A Tuveson
Journal:  Curr Opin Genet Dev       Date:  2019-03-04       Impact factor: 5.578

6.  Cancer associated fibroblast: Mediators of tumorigenesis.

Authors:  Jennifer Alexander; Edna Cukierman
Journal:  Matrix Biol       Date:  2020-05-22       Impact factor: 11.583

7.  Stem Cell Factor LIFted as a Promising Clinical Target for Cancer Therapy.

Authors:  Yu Shi; Sean Hunter; Tony Hunter
Journal:  Mol Cancer Ther       Date:  2019-08       Impact factor: 6.261

8.  Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.

Authors:  Ivy X Chen; Vikash P Chauhan; Jessica Posada; Mei R Ng; Michelle W Wu; Pichet Adstamongkonkul; Peigen Huang; Neal Lindeman; Robert Langer; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-30       Impact factor: 11.205

9.  Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.

Authors:  Honglin Jiang; Robert J Torphy; Katja Steiger; Henry Hongo; Alexa J Ritchie; Mark Kriegsmann; David Horst; Sarah E Umetsu; Nancy M Joseph; Kimberly McGregor; Michael J Pishvaian; Edik M Blais; Brian Lu; Mingyu Li; Michael Hollingsworth; Connor Stashko; Keith Volmar; Jen Jen Yeh; Valerie M Weaver; Zhen J Wang; Margaret A Tempero; Wilko Weichert; Eric A Collisson
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

Review 10.  The mesenchymal context in inflammation, immunity and cancer.

Authors:  Vasiliki Koliaraki; Alejandro Prados; Marietta Armaka; George Kollias
Journal:  Nat Immunol       Date:  2020-08-03       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.